Perioperative Nivolumab in Resectable Lung Cancer
Perioperative Nivolumab in Resectable Lung Cancer
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
In a trial assessing the perioperative use of nivolumab in resectable non–small-cell lung cancer (NSCLC), Cascone et al. (May 16 issue)
1
found significantly longer event-free survival with nivolumab plus chemotherapy than with neoadjuvant chemotherapy plus placebo. These data confirm that we are approaching a new era in the...
Alternative Titles
Full title
Perioperative Nivolumab in Resectable Lung Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3090638070
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3090638070
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMc2407267
